Call(s) to Action: None Here are the stories that the GeoTeam is following today… (Please see full disclosures at bottom) ChinaHybrids CHSTY ($21.11) – Taking a closer look at CHSTY because the company has reported profits for first half of […]
Call(s) to Action: None Here are the stories that the GeoTeam is following today… (Please see full disclosures at bottom) ChinaHybrids BONA ($7.49) reported Q2 2014 results, reported non-GAAP EPS of $0.05 vs $0.04 on a 58% increase in revenues. […]
Sgoco Group (NASDAQ:SGOC) ($1.62 marked up in pre market) – a company focused on product design, distribution and brand development in the China display market, today announced, a new on-line sales platform on JD.com to accelerate the delivery of high […]
Sciclone Pharmaceuticals (NASDAQ:SCLN)($6.79) – and its partner BTG plc (LSE: BTG), today announced, that the China Food and Drug Administration has approved the registration of DC Bead for the embolization of malignant hypervascularized tumors. BTG and SciClone previously entered into […]
Call(s) to Action: XXII, DGLY, NHTC, VRYAF The GeoTeam offers it own rebuttal to XXII’s response to GeoInvesting’s article, “22nd Century Group: A Lot Of Smoke, Not Enough Fire”. We disagree with the rebuttal by XXII’s management and stand by […]
Summary We offer a rebuttal to all four of XXII’s counterarguments to our piece published Wednesday (yesterday) morning. Rather than worry about the nuanced arguments XXII made in its rebuttal, we believe investors should be more interested in what XXII […]
While doing our research, we’ve noted a lot of company press releases that seem impressive on the surface, but that have all ultimately led to where the company is now-poised for more dilution and continually posting losses. When considering whether […]
A commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. INSY announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioblastoma multiforme (GBM), the […]